Unveiling Ac4C Modification Pattern: a Prospective Target for Improving the Response to Immunotherapeutic Strategies in Melanoma

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2025 Mar 6

PMID 40050821

Authors

Jianlan Liu

Pengpeng Zhang

Chaoqin Wu

Binlin Luo

Xiaojian Cao

Jian Tang

Affiliations

Soon will be listed here.

Abstract

Emerging evidence has confirmed the inextricable connection between N4-acetylcytidine (ac4C) mRNA modification and the clinical characteristics of malignancies. Nonetheless, it is uncertain whether and how ac4C mRNA modification patterns affect clinical outcomes in melanoma patients. This research integrated single-cell sequencing data and transcriptomics to pinpoint ac4C-related genes (acRG) linked to melanoma progression and evaluate their clinical implications. Cells with elevated acRG score were predominantly located within the melanocytes cluster. Intercellular communications between melanocytes and other cell subtypes were markedly strengthened in the acRG-high group. We developed and confirmed an excellent acRG-related signature (acRGS) utilizing a comprehensive set of 101 algorithm combinations derived from 10 machine learning algorithms. Hereby, the acRGS, including MYO10, ZNF667, MRAS, SCO2, MAPK10, PNMA6A, KPNA2, NT5DC2, BAIAP2L2 and NDST3, delineated ac4C-associated mRNA modification patterns in melanoma. The acRGS possesses distinctly superior performance to 120 previously reported signatures in melanoma and could predict the overall survival of melanoma patients across four external datasets. The substantial associations among immune checkpoint genes, immune cell infiltration, and tumor mutation burden with acRGS indicate that acRGS is helpful in identifying melanoma patients who are sensitive to immunotherapy. Besides, we confirmed that MYO10 was mainly overexpressed in melanoma tissues, and elevated MYO10 was positively correlated with malignant phenotypes and unfavorable prognosis in melanoma patients. Silencing MYO10 expression inhibited melanoma cell proliferation, migration and invasion in vitro as well as tumor growth in vivo. Taken together, the acRGS could function as a reliable and prospective tool to improve the clinical prognosis for melanoma individuals.

References

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Lim S, Rizos H . Single-cell RNA sequencing in melanoma: what have we learned so far?. EBioMedicine. 2024; 100:104969. PMC: 10831183. DOI: 10.1016/j.ebiom.2024.104969. View

Arango D, Sturgill D, Yang R, Kanai T, Bauer P, Roy J . Direct epitranscriptomic regulation of mammalian translation initiation through N4-acetylcytidine. Mol Cell. 2022; 82(15):2797-2814.e11. PMC: 9361928. DOI: 10.1016/j.molcel.2022.05.016. View

Makowska K, Hughes R, White K, Wells C, Peckham M . Specific Myosins Control Actin Organization, Cell Morphology, and Migration in Prostate Cancer Cells. Cell Rep. 2015; 13(10):2118-25. PMC: 4688110. DOI: 10.1016/j.celrep.2015.11.012. View

Hu Z, Lu Y, Cao J, Lin L, Chen X, Zhou Z . -acetyltransferase NAT10 controls cell fates via connecting mRNA cytidine acetylation to chromatin signaling. Sci Adv. 2024; 10(2):eadh9871. PMC: 10786415. DOI: 10.1126/sciadv.adh9871. View

Carlino M, Larkin J, Long G . Immune checkpoint inhibitors in melanoma. Lancet. 2021; 398(10304):1002-1014. DOI: 10.1016/S0140-6736(21)01206-X. View

Liu Z, Liu L, Weng S, Guo C, Dang Q, Xu H . Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. Nat Commun. 2022; 13(1):816. PMC: 8831564. DOI: 10.1038/s41467-022-28421-6. View

Zhang Y, Zhang Z . The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8):807-821. PMC: 7395159. DOI: 10.1038/s41423-020-0488-6. View

Wolchok J, Chiarion-Sileni V, Gonzalez R, Grob J, Rutkowski P, Lao C . Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2021; 40(2):127-137. PMC: 8718224. DOI: 10.1200/JCO.21.02229. View

10.

Miao D, Shi J, Lv Q, Tan D, Zhao C, Xiong Z . NAT10-mediated acC-modified ANKZF1 promotes tumor progression and lymphangiogenesis in clear-cell renal cell carcinoma by attenuating YWHAE-driven cytoplasmic retention of YAP1. Cancer Commun (Lond). 2024; 44(3):361-383. PMC: 10962679. DOI: 10.1002/cac2.12523. View

11.

Bidkhori G, Narimani Z, Ashtiani S, Moeini A, Nowzari-Dalini A, Masoudi-Nejad A . Reconstruction of an integrated genome-scale co-expression network reveals key modules involved in lung adenocarcinoma. PLoS One. 2013; 8(7):e67552. PMC: 3708931. DOI: 10.1371/journal.pone.0067552. View

12.

Liu H, Xu L, Yue S, Su H, Chen X, Liu Q . Targeting N4-acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2-mediated HMGB2 mRNA translation. Cancer Commun (Lond). 2024; 44(9):1018-1041. PMC: 11492314. DOI: 10.1002/cac2.12595. View

13.

Tokuo H, Bhawan J, Coluccio L . Myosin X is required for efficient melanoblast migration and melanoma initiation and metastasis. Sci Rep. 2018; 8(1):10449. PMC: 6041326. DOI: 10.1038/s41598-018-28717-y. View

14.

Mattila P, Lappalainen P . Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008; 9(6):446-54. DOI: 10.1038/nrm2406. View

15.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

16.

Long G, Weber J, Infante J, Kim K, Daud A, Gonzalez R . Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016; 34(8):871-8. DOI: 10.1200/JCO.2015.62.9345. View

17.

Sun Y, Ai X, Shen S, Lu S . NF-κB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. Oncotarget. 2015; 6(10):8244-54. PMC: 4480748. DOI: 10.18632/oncotarget.3135. View

18.

Lv J, Dai B, Kong Y, Shen X, Kong J . Acral Melanoma in Chinese: A Clinicopathological and Prognostic Study of 142 cases. Sci Rep. 2016; 6:31432. PMC: 4992860. DOI: 10.1038/srep31432. View

19.

Xie L, Zhong X, Cao W, Liu J, Zu X, Chen L . Mechanisms of NAT10 as ac4C writer in diseases. Mol Ther Nucleic Acids. 2023; 32:359-368. PMC: 10148080. DOI: 10.1016/j.omtn.2023.03.023. View

20.

Jayawardana K, Schramm S, Haydu L, Thompson J, Scolyer R, Mann G . Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein information. Int J Cancer. 2014; 136(4):863-74. DOI: 10.1002/ijc.29047. View